Reaktionsgleichung
ClC1C=CC(OC2C=CC(CN3CCC([C:18]4[CH:19]=[C:20]([NH:24][C:25](=[O:29])[CH:26]([CH3:28])[CH3:27])[CH:21]=[CH:22][CH:23]=4)CC3)=CC=2)=CC=1.[C:34]1([N:40]2[C:48]3[C:43](=[CH:44][CH:45]=[CH:46][CH:47]=3)[C:42]([CH2:49][CH2:50][CH2:51][N:52]3[CH2:57][CH2:56][CH:55](C4C=C(NC(=O)C(C)C)C=CC=4)[CH2:54][CH2:53]3)=[C:41]2[C:70]2C=CC=C[CH:71]=2)[CH:39]=CC=CC=1.C(N1C2C=CC(C=O)=CC=2C2C1=CC=CC=2)C.CC(C)C(NC1C=CC(C2CCNCC2)=CC=1)=O>>[CH2:34]([N:40]1[C:41]2[CH:70]=[CH:71][C:50]([CH2:51][N:52]3[CH2:53][CH2:54][CH:55]([C:23]4[CH:22]=[CH:21][C:20]([NH:24][C:25](=[O:29])[CH:26]([CH3:27])[CH3:28])=[CH:19][CH:18]=4)[CH2:56][CH2:57]3)=[CH:49][C:42]=2[C:43]2[C:48]1=[CH:47][CH:46]=[CH:45][CH:44]=2)[CH3:39]Komponenten
Edukt 4
Produkt 1
Versuchsvorschrift
According to the procedure used for the synthesis of N-(3-{1-[4-(4CHLOROPHENOXY)BENZYL]-4-PIPERIDINYL}PHENYL)-2-METHYLPROPANAMIDE (Example 108) N-(3-{1-[3-(1,2-diphenyl-1H-indol-3-yl)propyl]-4-piperidinyl}phenyl)-2-methylpropanamide, 9-ethyl-9H-carbazole-3-carbaldehyde (22.3 mg, 0.100 mmol) and 2-methyl-N-[4-(4-piperidinyl)phenyl]propanamide (24.6 mg, 0.100 mmol) provided N-(4-{1-[(9-ethyl-9H-carbazol-3-yl)methyl]-4-piperidinyl}phenyl)-2-methylpropanamide. The product was obtained as a white crystalline solid (20 mg, 44%). 1H NMR (400 MHz, CDCl3) δ 8.21–7.09 (m, 12H), 4.38 (q, 2H, J=7.2 Hz), 3.81 (s, 2H), 3.25–3.03 (m, 2H), 2.60–2.38 (m, 2H), 2.31–2.09 (m, 2H), 1.98–1.69 (m, 4H), 1.44 (t, 3H, J=7.2 Hz), 1.23 (d, 6H, J=6.8 Hz); ESMS m/e: 454.3 (M+H)+.
Quellen und Nachweise
- ORD-Eintrag
- ord-005654c189b24fd78208604ae945d78c
- Quelldatensatz
- uspto-grants-2006_06
- Patentnummer
- US07067534B1
Verknüpfte Notizen
Wird geladen…